---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-096709"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:49:03.974709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M

## Summary
- Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.
- Preliminary cash, equivalents and securities ~$187.9M as of Dec 31, 2025 (unaudited).
- Net proceeds extend runway into H1 2028; funds pipeline development, BD, and G&A.
- Investors include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, and others.
- Private placement expected to close March 9, 2026; Leerink and Citi lead placement agents.

## SEC filing metadata
- accession: 0001193125-26-096709
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/0001193125-26-096709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-096709
- JSON: https://secwatch.observer/filing/0001193125-26-096709.json
- Plain text: https://secwatch.observer/filing/0001193125-26-096709.txt

## Key facts
- Material Agreements
  Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $240.0 million (effective 2026-03-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: approximately $240.0 million
  - Effective: 2026-03-06
  source text: On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/0001193125-26-096709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.